BMS-986142 is primarily utilized in the field of medical research and drug development. It functions as a potent and selective inhibitor of BTK (Bruton's tyrosine kinase), which plays a crucial role in B-cell signaling pathways. This makes it a promising candidate for the treatment of various autoimmune diseases and B-cell malignancies, such as rheumatoid arthritis and certain types of leukemia or lymphoma. By inhibiting BTK, it helps modulate immune responses and reduce inflammation, offering potential therapeutic benefits for patients with these conditions. Ongoing clinical trials aim to evaluate its efficacy and safety in treating these diseases.